MGMT and neoplasm: Although epigenetic inactivation of MGMT is present in approximately 40% of newly diagnosed glioblastoma, the remaining tumours have normal or even elevated levels of MGMT and are resistant to treatment with temozolomide (Esteller et al, 1999; Paz et al, 2004).